Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals
Mandate

CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals

May 10, 2005

Solvay Pharmaceuticals, the Belgium based pharmaceuticals firm, has agreed to acquire NeoPharma AB, the Sweden based pharmaceuticals firm involved in development of drugs for the treatment of Parkinson's disease, from 3i Group plc, the UK based private equity firm, and CapMan, the Finnish private equity firm, in a transaction, for approximately SEK 640m (EUR 71.26m).

Vinge acted for the sellers, being private investors as well as private equity funds including 3i and CapMan.
Anders Åberg, Malin Ohlin Åkermark (reponsible partners)
Maja Wettergren, Ola Sandersson (associates)

Related

Vinge has advised Studentbostäder i Norden AB in connection with its rights issue

 Vinge has advised Studentbostäder i Norden AB (publ), a real estate company whose shares are listed on Nasdaq First North Premier Growth Market, in connection with an oversubscribed rights issue amounting to approximately SEK 145 million before deduction of transaction costs.
April 25, 2025

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB

 Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB
April 24, 2025

Vinge advises Biotage in connection with RWK Bidco’s public tender

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.
April 22, 2025